نتائج البحث - "Johanna C. Bendell"

المصدر: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for immunotherapy of cancer, 9(7):002446. BMC

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Gastroenterology, B7-H1 Antigen, 0302 clinical medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immunology and Allergy, Prodrugs, Immune Checkpoint Inhibitors, RC254-282, Clinical/Translational Cancer Immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Antibodies, Monoclonal, Middle Aged, Oncology, Tolerability, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Toxicity, Molecular Medicine, Female, immunotherapy, medicine.drug, Adult, CTLA-4 antigen, medicine.medical_specialty, Combination therapy, Immunology, therapies, Ipilimumab, investigational, 03 medical and health sciences, Internal medicine, medicine, Humans, Testicular cancer, Pneumonitis, Aged, Pharmacology, Dose-Response Relationship, Drug, business.industry, medicine.disease, 030104 developmental biology, NIVOLUMAB PLUS IPILIMUMAB, PD-L1 inhibitor, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f59b5f6c6c998d04c0063e8f4efa570Test
https://pubmed.ncbi.nlm.nih.gov/34301808Test

5

419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial

المؤلفون: Ryan Geschwindt, Thomas B. Karasic, Kevin O’Hayer, Susan Spitz, Johanna C. Bendell, Solmaz Sahebjam, Janice M. Mehnert, Tara C. Mitchell, Hao Liu, Sarina Anne Piha-Paul

المصدر: Regular and young investigator award abstracts.

مصطلحات موضوعية: LAG3, biology, business.industry, T cell, Pharmacology, Granzyme B, medicine.anatomical_structure, Pharmacokinetics, medicine, biology.protein, Antibody, business, Granzyme H, Ex vivo, Whole blood

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::f3116986116f398aa856638cc42a21f7Test
https://doi.org/10.1136/jitc-2020-sitc2020.0419Test

6

482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors

المؤلفون: Christopher Korth, George Dranitsaris, Judy Wang, Filip Janku, Johanna C. Bendell, Joseph Bolen, Amit Mahipal, Eric Elenko, Aleksandra Filipovic, Zev Wainber, Manish Sharma

المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

مصطلحات موضوعية: Pharmacology, Cancer Research, biology, business.industry, Immunology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Oncology, Cancer research, biology.protein, Molecular Medicine, Immunology and Allergy, Medicine, In patient, Antibody, business, RC254-282, Galectin

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a8aecce24e1ae86b9da9c66ed7a040eTest
https://doi.org/10.1136/jitc-2021-sitc2021.482Test

7

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

المؤلفون: Herbert Hurwitz, Vaibhav Sahai, Chris Verslype, Jason Clark, Johanna C. Bendell, Ashwin Reddy Sama, Eric Van Cutsem, Manuel Hidalgo, Edward W Greeno, Eileen M. O'Reilly, Chung Pin Li, Kenneth H. Yu, Christopher James Walker, Fitzroy Dawkins, Teresa Macarulla, Marcelo Garrido Salvo

المصدر: Investigational New Drugs. 36:683-695

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Ruxolitinib, Placebo, Disease-Free Survival, Article, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Pancreatic cancer, Antineoplastic Combined Chemotherapy Protocols, Nitriles, medicine, Clinical endpoint, Humans, Pharmacology (medical), Aged, Aged, 80 and over, Pharmacology, business.industry, Hazard ratio, Janus Kinase 1, Janus Kinase 2, Middle Aged, medicine.disease, Chemotherapy regimen, Pancreatic Neoplasms, Clinical trial, Pyrimidines, 030104 developmental biology, 030220 oncology & carcinogenesis, Disease Progression, Pyrazoles, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4efb9dd95fab56ab09c97a08030248fTest
https://doi.org/10.1007/s10637-018-0580-2Test

8

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

المصدر: European Journal of Cancer. 138:S8-S9

مصطلحات موضوعية: Cobimetinib, Clinical trial, Cancer Research, chemistry.chemical_compound, Intermittent dosing, Oncology, chemistry, business.industry, MEK inhibitor, Medicine, Pharmacology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::cea90f2fbed5f0dc76f0ee78179f0c29Test
https://doi.org/10.1016/s0959-8049Test(20)31089-3

9

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers

المؤلفون: Erika Hamilton, Hani Gabra, Kathleen M. Moore, Jennifer R. Diamond, Mark Poole, D. Ross Camidge, Martin D. Forster, Michael S. Gordon, David M. Waterhouse, Barbara A. Goff, Carolyn D. Britten, Johanna C. Bendell

المصدر: Invest New Drugs

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Mitochondrial inhibitor, Cell, Uterine Cervical Neoplasms, Neutropenia, Article, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Stable Disease, Pharmacokinetics, Ovarian cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, ME-344, Pharmacology (medical), Oncology & Carcinogenesis, Aged, Ovarian Neoplasms, Pharmacology, Lung, Dose-Response Relationship, Drug, Small cell lung cancer, business.industry, Middle Aged, medicine.disease, Isoflavones, Mitochondria, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Toxicity, Female, 1115 Pharmacology And Pharmaceutical Sciences, Topotecan, Neoplasm Recurrence, Local, Topoisomerase I Inhibitors, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14dee4e7e022a14638395d5059e46ddfTest
https://doi.org/10.1007/s10637-017-0444-1Test

10

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

المؤلفون: Jean-Luc Van Laethem, Frederico Longo Muñoz, Thea Kalebic, Khaldoun Almhanna, Maria Alsina, Carolina Muriel Lopez, Antonio Cubillo Gracian, Hadi Danaee, Irfan Firdaus, Zhan Ye, Adedigbo Fasanmade, Johanna C. Bendell, Wells A. Messersmith, David Wright, Richard A. Hubner, Maria Luisa Limon Miron

المصدر: Investigational New Drugs. 35:235-241

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, Immunoconjugates, Esophageal Neoplasms, Receptors, Enterotoxin, Phases of clinical research, Antineoplastic Agents, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Neutropenia, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Stomach Neoplasms, Internal medicine, medicine, Humans, Pharmacology (medical), Gastrointestinal cancer, Aged, Aged, 80 and over, Pharmacology, business.industry, Guanylate cyclase 2C, Middle Aged, medicine.disease, Interim analysis, Tumor Burden, Surgery, Treatment Outcome, 030104 developmental biology, Oncology, Monomethyl auristatin E, chemistry, 030220 oncology & carcinogenesis, Female, Esophagogastric Junction, Neoplasm Recurrence, Local, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15e4a2ebe65fb4b73b1a74204841d4eaTest
https://doi.org/10.1007/s10637-017-0439-yTest

تنقيح النتائج